JPRN-jRCT2031210481招募中2 期
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis
ishiura Tomoyuki0 个研究点目标入组 8 人开始时间: 2021年12月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •Diagnosis of Systemic Sclerosis according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2013 criteria
- •-Systemic Sclerosis patients with moderate to sever skin sclerosis
排除标准
- •-Patients witg a disease considered inappropriate for participation in clinical trials, such as serious cardiac / hepatic / renal / pulmonary / hematologic disease
- •-Patients with a diseases that could interfere with assessment of Systemic Scleorosis
- •-Patients with body weight less than 30.0kg
- •-Pregnant or lactating women.
研究者
相似试验
进行中（未招募）
1 期
Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPCProgressive Metastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000209-10-DKAstraZeneca AB80
进行中（未招募）
1 期
Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPCProgressive Metastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000209-10-DEAstraZeneca AB80
进行中（未招募）
1 期
Phase II two-arm study of AZD4635 in combination with durvalumab and in combination with cabazitaxel and durvalumab in patients with mCRPCProgressive Metastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000209-10-NLAstraZeneca AB80
进行中（未招募）
1 期
A Phase 2, Open label Study to Assess the Efficacy and Safety of Tenalisib(RP6530) in Patients with Relapsed/Refractory Chronic LymphocyticLeukemia (CLL)Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2019-003622-25-PLRhizen Pharmaceuticals SA61
进行中（未招募）
不适用
A Phase II, open-label study to assess the efficacy and tolerability of ZD6474 ZACTIMA 100 mg monotherapy in subjects with locally advanced or metastatic hereditary medullary thyroid cancer - NDocally advanced or metastatic hereditary medullary thyroid cancerMedDRA version: 9.1Level: LLTClassification code 10027105Term: Medullary thyroid cancerEUCTR2006-001354-28-ITASTRAZENECA15